独立董事候选人声明与承诺 本人李学金，已充分了解并同意由提名人深圳市亚辉龙生物科技股份有限公 司董事会提名为深圳市亚辉龙生物科技股份有限公司第四届董事会独立董事候 选人。本人公开声明，本人具备独立董事任职资格，保证不存在任何影响本人担 任深圳市亚辉龙生物科技股份有限公司独立董事独立性的关系，具体声明并承诺 如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独立 董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （五）中共中央组织部《关于进一步规范党政领导干部在企业兼职（任职） 问题的意见》的相关规定（如适用）； （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的 意见》的相关规定（如适用）； （七）中国人民银行《股份制商业银行独立董事和外部监事制度指引》等的 相关规定（如适用）； （八）中国证监会《证券基金经营机构董事、监事、高级管理人员及从业人 员监督管理办法》等的相关规定（如适用）； （九）《银行业金融机构董事（理事）和高级管理人员任职资格管理办法》 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2024-070 深圳市亚辉龙生物科技股份有限公司 关于自愿披露全资子公司取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，深圳市亚辉龙生物科技股份有限公司（以下简称"公司"或"亚辉龙"）全 资子公司湖南亚辉龙生物科技有限公司收到了由湖南省药品监督管理局签发的医疗器 械注册证，具体信息如下: 一、医疗器械注册证的基本情况 | 序 号 | 产品名称 | 注册编号 | 注册证有效期 | 注册 分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 全自动生化分析仪 | 湘械注准 20242221185 | 至 2029/11/21 | 二类 | 用于对人体体液（全血、血清、血浆、 尿液、脑脊液等）样本中的成分进行 | | | | | | | 定量检测。 | | | 抗 β2 糖蛋白 I 结构域 | 湘 械 注 准 | | | 用于体外定量测定人血清中的抗 β2 糖蛋白 I 结构域 1 IgG ...

Group 1: Investor Relations Activities - A total of 14 events were held from November 6 to 15, 2024 [1] - 26 institutions participated, with a total of 27 attendees [1] - Activities included company tours, analyst meetings, media interviews, performance briefings, and roadshows [1] Group 2: Participating Institutions - Notable institutions included Zhongyou Fund, Guoshou Asset, and Tianhong Fund among others [2] - The list comprises 26 different investment institutions [2] - The institutions represent a diverse range of asset management and investment strategies [2]

Investment Rating - Buy / Maintain [1] Core Views - The company's Q3 performance is under temporary pressure, but its chemiluminescence revenue continues to grow at a high rate [1] - The company's non-COVID self-produced business achieved revenue of 1,142 million yuan, a year-on-year increase of 24.40%, with chemiluminescence business revenue reaching 1,037 million yuan, up 29.15% year-on-year [1] - Overseas chemiluminescence business revenue grew by 45.71% year-on-year, reaching 134 million yuan [1] - The company's gross profit margin increased significantly due to changes in product structure, with the comprehensive gross profit margin rising by 10.32 percentage points to 63.69% [1] Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 1,394 million yuan, a year-on-year decrease of 9.78%, and net profit attributable to the parent company of 219 million yuan, a year-on-year decrease of 23.29% [1] - In Q3 2024, the company's operating revenue was 434 million yuan, a year-on-year decrease of 7.69%, and net profit attributable to the parent company was 46 million yuan, a year-on-year decrease of 68.21% [1] - The company's operating cash flow increased by 164.90% year-on-year to 318 million yuan in the first three quarters of 2024 [1] Instrument Installation and Market Performance - The company installed 1,727 new self-produced chemiluminescence instruments in the first nine months of 2024, with 995 installed domestically and 732 overseas [1] - The company installed 61 new production lines, a year-on-year increase of 74.29% [1] - As of September 30, 2024, the cumulative installation of self-produced chemiluminescence instruments exceeded 9,980 units, with over 150 production lines installed [1] Revenue Breakdown - The company's self-produced chemiluminescence business revenue reached 1,037 million yuan, a year-on-year increase of 29.15% [1] - Revenue from autoimmune diagnostic reagents increased by 31.41% year-on-year, and myocardial marker diagnostic reagents increased by 49.84% year-on-year [1] - Biochemical diagnostic business revenue grew by 37.11% year-on-year [1] Expense Analysis - Sales expenses increased by 6.47% year-on-year to 300 million yuan, with a sales expense ratio of 21.50% [1] - Management expenses increased by 0.37% year-on-year to 126 million yuan, with a management expense ratio of 9.03% [1] - R&D expenses increased by 7.13% year-on-year to 229 million yuan, with an R&D expense ratio of 16.46% [1] - Financial expenses increased to 6 million yuan, with a financial expense ratio of 0.45% [1] Profitability Forecast - The company's revenue is expected to be 2,117 million yuan in 2024, 2,602 million yuan in 2025, and 3,124 million yuan in 2026, with year-on-year growth rates of 3%, 23%, and 20% respectively [2] - Net profit attributable to the parent company is expected to be 376 million yuan in 2024, 509 million yuan in 2025, and 650 million yuan in 2026, with year-on-year growth rates of 6%, 35%, and 28% respectively [2] - The company's PE ratio is 27.24x for 2024, 20.11x for 2025, and 15.76x for 2026 [3] Balance Sheet and Cash Flow - The company's total assets are expected to be 3,929 million yuan in 2024, 4,327 million yuan in 2025, and 4,868 million yuan in 2026 [4] - Operating cash flow is expected to be 729 million yuan in 2024, 680 million yuan in 2025, and 800 million yuan in 2026 [4] - The company's ROE is expected to be 13.40% in 2024, 16.14% in 2025, and 17.83% in 2026 [4]

（以下无正文） 关于深圳市亚辉龙生物科技股份有限公司 控股股东、实际控制人：胡鹍辉 股票交易严重异常波动有关事项问询函的回函 2024 年 11 月 7 日 致：深圳市亚辉龙生物科技股份有限公司 本人已收到贵司发来的《关于深圳市亚辉龙生物科技股份有限公司股票交易 严重异常波动有关事项的问询函》，经认真自查，现就有关情况回复如下： 截至本函签署日，作为公司的控股股东及实际控制人，不存在影响上市公司 股票交易严重异常波动的重大事项；不存在应披露而未披露的重大事项，包括但 不限于重大资产重组、股份发行、债务重组、业务重组、资产剥离和资产注入等 重大事项。 本人在股票交易严重异常波动期间不存在买卖公司股票的情况。 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2024-069 深圳市亚辉龙生物科技股份有限公司 股票交易严重异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）股票交易连续 30 个交易日内（2024 年 9 月 20 日至 2024 年 11 月 7 日）收盘价格跌幅偏离值累计达到 70% 以上，根据《上海证券交易所科创板股票上市规则》（以下简称《科创板上市规则》） 《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的 有关规定，属于股票交易严重异常波动情形。 经公司自查，并发函问询控股股东、实际控制人，截至 2024 年 11 月 7 日，无 应披露而未披露的重大事项。 截至 2024 年 11 月 7 日，公司收盘价为 18.26 元/股。根据中证指数有限公司发 布的数据，截至 2024 年 11 月 7 日，公司最新滚动市盈率为 36.08 倍，公司所处的医药 制造业最近一个月平均滚动市盈率为 27.03 ...

Investment Rating - Outperform rating with a target price range of 21.23-23.42 RMB, implying a 15.9-27.9% upside from the current price [1][3] Core Views - The company is a leading domestic brand in chemiluminescence, with a complete product portfolio covering high, medium, and low-end models and intelligent assembly lines [1] - The chemiluminescence business is the core growth driver, with revenue growing from 140 million RMB in 2018 to 1.17 billion RMB in 2023, a CAGR of over 50% [1] - The company has a strong presence in key areas such as autoimmune diseases, reproductive health, diabetes, infectious diseases, liver diseases, and cardiovascular diseases [1] - The company's strategy of "specialized entry, routine expansion" has been effective, with routine diagnostic reagent revenue growing 50.20% YoY in 2023 and 52.48% YoY in H1 2024 [1] - The company is expanding internationally, with overseas non-COVID business revenue growing rapidly, driven by partnerships such as with Japan's MBL [1] Industry Overview - The global in-vitro diagnostics (IVD) market is expected to reach 106.5 billion USD in 2023, with a CAGR of 3.8% from 2023-2028 [21] - The Chinese IVD market is expected to reach 120 billion RMB in 2023, with immunodiagnostics being the largest segment at 37.5 billion RMB, growing 13% YoY [21][23] - Chemiluminescence is the mainstream advanced technology in immunodiagnostics due to its high sensitivity, wide linear range, and rapid clinical application [23] - The domestic autoimmune diagnostics market is estimated at 1.5-2 billion RMB, with significant growth potential as autoimmune diseases become more recognized and treated [1][27] Company Performance and Strategy - The company's revenue grew from 722 million RMB in 2018 to 1.676 billion RMB in 2023, with a CAGR of 18.3% [17] - Non-COVID self-produced business revenue grew from 246 million RMB in 2018 to 1.326 billion RMB in 2023, a CAGR of 40.1% [17] - The company has a comprehensive product menu with 176 chemiluminescence diagnostic items, leading the industry in autoimmune diagnostics with 60 items [33] - The company has achieved wide coverage in high-grade hospitals, with over 35% of its total installations in Tier 3 and above hospitals [35] - The company is expanding its product line with new technologies such as multi-detection and microfluidics, and aims to increase self-produced raw material rate to over 80% in the next 3-5 years [38] Financial Projections - Revenue is projected to be 2.044 billion RMB in 2024, 2.502 billion RMB in 2025, and 3.078 billion RMB in 2026, with YoY growth rates of -0.5%, 22.4%, and 23.1% respectively [1] - Net profit is projected to be 381 million RMB in 2024, 513 million RMB in 2025, and 667 million RMB in 2026, with YoY growth rates of 7.4%, 34.5%, and 30.0% respectively [1] - EPS is projected to be 0.67 RMB in 2024, 0.90 RMB in 2025, and 1.17 RMB in 2026, with a current PE ratio of 27x, 20x, and 16x respectively [1]

证券代码：688575 证券简称：亚辉龙 公告编号：2024-067 深圳市亚辉龙生物科技股份有限公司 关于 2023 年限制性股票激励计划第一个归属期 归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 991,500 股。 本次股票上市流通总数为 991,500 股。 本次股票上市流通日期为 2024 年 11 月 7 日。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）收到中国证券登记结 算有限责任公司上海分公司于 2024 年 11 月 1 日出具的《证券变更登记证明》，公 司完成了 2023 年限制性股票激励计划（以下简称"本激励计划"）第一个归属期的 股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 1、2023 年 9 月 14 日，公司召开第三届董事会第十六次会议，审议通过了《关 于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年 ...

Summary of Conference Call Records Company and Industry Overview - The conference call discusses the performance and strategic direction of a company in the chemical luminescence diagnostics industry, specifically focusing on its recent quarterly results and future outlook. Key Points and Arguments Financial Performance - For the first three quarters of 2024, the company reported total revenue of **1.394 billion** (13.94亿), a year-on-year decline of **9.78%** [2] - Non-COVID related revenue was **1.142 billion** (11.42亿), showing a growth of **24.4%** year-on-year [2] - The company’s gross margin for the first three quarters was **63.36%**, an increase of **10 percentage points** from the previous year [3] - The revenue from the chemical luminescence business was **1.037 billion** (10.37亿), a year-on-year increase of **29.15%** [4] Business Segments - Domestic non-COVID related revenue was **993 million** (9.93亿), up **22%** year-on-year, while international revenue was **149 million** (1.49亿), up **41.34%** [2] - The company’s sales expenses increased by **6.47%**, while management expenses remained stable with a growth of **0.37%** [4] - R&D expenses were **229 million** (2.29亿), maintaining a rate of **16%** of total revenue [4] Market Dynamics - The company is facing inventory challenges due to rapid growth and is actively working on inventory reduction strategies [1][10] - The inventory turnover period is currently around **4.8 months**, with a target to normalize to **2-3 months** [11] - The company is committed to cost reduction and efficiency improvements, particularly in raw material sourcing [10][14] Future Outlook - The company aims for its chemical luminescence business to grow at a rate of **30%** over the next three to five years [15][17] - The company is expanding its market presence internationally, particularly in regions like the Middle East and South Asia [18] - The introduction of new products and enhancements in service delivery are expected to drive future growth [24] Strategic Initiatives - The company has signed partnerships for laboratory automation systems to enhance operational efficiency [6] - A new training service center in Cairo has been established to support local service capabilities [7] - The company is focusing on increasing its market share in the self-testing diagnostics segment, which is projected to grow significantly [35][36] Regulatory Environment - The upcoming implementation of centralized procurement policies is expected to impact pricing and market dynamics, but the company views this as an opportunity for growth in market share [26][28] - The company is preparing for the second round of centralized procurement, which may lead to increased competition but also greater opportunities for domestic products [26] Challenges and Risks - The company acknowledges the impact of DRGs (Diagnosis-Related Groups) on testing volumes, which may affect revenue in the short term [30][32] - There is a recognition of the need to adapt to changing market conditions and regulatory frameworks to maintain competitive advantage [32][40] Additional Important Content - The company has achieved significant milestones in product development and market penetration, including the launch of new diagnostic solutions and enhancements in existing product lines [39] - The focus on academic collaborations and partnerships is seen as a key strategy for driving innovation and expanding market reach [7][18] This summary encapsulates the essential insights from the conference call, highlighting the company's financial performance, strategic initiatives, market dynamics, and future outlook within the chemical luminescence diagnostics industry.